GC Biopharma Unveils ALYGLO™ for Immunodeficiency Treatment
GC Biopharma Launches ALYGLO™ for Immune Treatment
GC Biopharma USA, Inc. has exciting news about its groundbreaking immunoglobulin product, ALYGLO (immune globulin intravenous, human-stwk). This innovative therapy is now available in the marketplace for adult patients aged 17 years and older suffering from primary humoral immunodeficiency (PI). This condition is quite rare and chronic, reflecting a significant challenge as the body's ability to produce antibodies is compromised, leading to increased vulnerability to infections.
The Significance of ALYGLO for Patients
For individuals with PI, ALYGLO represents a vital treatment option. This disorder impairs the immune defenses, accentuating the need for effective therapies. ALYGLO has impressively met primary safety and efficacy endpoints as mandated by the FDA in rigorous Phase 3 clinical trials. A noteworthy aspect of ALYGLO is its sophisticated manufacturing process, incorporating Cation Exchange Chromatography (CEX) to remove coagulation factor XIa (FXIa) to levels that are undetectable. The medication received FDA approval on Dec. 15, 2023.
Dr. Eun Chul Huh’s Vision
Dr. Eun Chul Huh, President and CEO of GC Biopharma, emphasizes the launch's importance, describing it as a historic milestone. "The US launch of ALYGLO exemplifies our commitment to enhancing the health and lives of individuals facing rare diseases globally," he stated. This initiative showcases GC Biopharma's mission of investing in research and development to curate several future products that will positively impact the US healthcare landscape.
Accessible Distribution Network for Patients
ALYGLO will be accessible to both patients and healthcare professionals via a carefully selected limited distribution network of premier national Specialty Pharmacy providers. This strategy guarantees a wide-reaching availability, which is essential for those diagnosed with primary immune deficiencies. Additionally, ALYGLO can also be sourced through specialty distributors across the United States.
Statement from Dr. Lisa Betts
Dr. Lisa Betts, the Chief Operating Officer for GC Biopharma USA, Inc., expressed her enthusiasm: "ALYGLO significantly expands treatment options, enhancing access in the US marketplace. Our goal is to provide life-saving therapies to individuals with rare diseases, and we are thrilled to introduce another immune globulin therapeutic alternative for patients."
Understanding Primary Humoral Immunodeficiency (PI)
Primary Humoral Immunodeficiency (PI) encompasses various disorders characterized by the body's inability to produce adequate antibodies. This incapacity leads to increased vulnerability to infections, particularly bacterial ones affecting respiratory and gastrointestinal systems. The conditions treated by ALYGLO include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies—all illustrating the crucial need for effective treatment options.
About ALYGLO
ALYGLO offers a 10% solution of immunoglobulin G intended for intravenous infusion, sourced from pooled human plasma. The thorough production process includes critical steps to mitigate the risk of virus transmission, such as fractionation, solvent/detergent treatment, and nanofiltration. The use of advanced CEX technology during manufacturing ensures the removal of FXIa, further enhancing safety.
About GC Biopharma Corp.
With a legacy spanning over half a century, GC Biopharma Corp. (previously known as Green Cross Corporation) stands as a biopharmaceutical trailblazer, delivering vital protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma dedicates itself to facilitating quality healthcare solutions on a global scale.
About GC Biopharma USA, Inc.
Founded in 2018 in Teaneck, NJ, GC Biopharma USA, Inc. specializes in sales, marketing, and business strategies to serve patients and healthcare providers across the US. Backed by the substantial expertise of its parent company, GC Biopharma USA aims to broaden its influence and provide world-class plasma therapies and vaccines.
Frequently Asked Questions
What is ALYGLO used for?
ALYGLO is utilized for treating primary humoral immunodeficiency in adults, enhancing the body’s ability to combat infections.
How is ALYGLO manufactured?
ALYGLO is produced using advanced processes including Cation Exchange Chromatography to ensure safety and efficacy.
Who can prescribe ALYGLO?
ALYGLO can be prescribed by qualified healthcare professionals to adult patients diagnosed with primary humoral immunodeficiency.
What safety information should I know about ALYGLO?
Important safety information includes potential allergic reactions and the need for monitoring during infusion. Patients should discuss any concerns with their healthcare provider.
How can patients obtain ALYGLO?
Patients can acquire ALYGLO through a limited distribution network of national Specialty Pharmacy partners and specialty distributors in the United States.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Progress Software Set to Acquire ShareFile for Real Growth
- Jefferies Predicts Modest Expectations for iPhone 16 Sales
- Oracle Earnings Forecast: Analyst Insights and Stock Ratings
- Astrix Security Teams Up with GuidePoint for Enhanced NHI Protection
- Five Point Energy Secures $1.4 Billion for New Infrastructure Fund
- Moleculin Starts Patient Treatment in Phase 2 Glioblastoma Trial
- Sinch Initiates New Funding Strategy for Growth and Expansion
- Mudra Link: Revolutionizing Gesture Control for All Platforms
- Accredited Solutions Initiates $3.6M Journey for Growth and Acquisitions
- New International Certification for Healthcare Sustainability Launched
Recent Articles
- Transforming Marketing Strategies with SearchStax and Magnolia
- Harris and Trump Tied in Latest Polls, Shift in Voter Sentiment
- Fall Flavors and Savings: Enjoy Panera Bread Delights
- Revolutionizing Search Experiences: SearchStax and Magnolia's Alliance
- Realtor.com® Unveils Cutting-Edge AI Renovation Tool
- Innovative Student-Crafted Metaverse Premieres in New York
- KBR Partners with Zhejiang Petroleum for Major SDA Project
- FDA Grants GRAS Status to Innodal's Food Processing Innovation
- Social Media's Rising Influence on Young Tradespeople Careers
- James Grimaldi Becomes Executive Editor of National Catholic Reporter
- Challenges Faced by Luxury Brands Amid Global Economic Shifts
- Jimmy Lai's Media Firm Challenges BDO Amid Political Turmoil
- Exploring Current Economic Stability Amidst Recession Fears
- Morgan Stanley Adjusts Brent Crude Price Forecasts Downward
- Growth Projections for the Opioid Overdose Treatment Market
- Glass Flake Coatings Market Expected to Reach $4.09 Billion
- Radware Partners with Cirion Technologies for Enhanced Security
- Understanding Recent Fund Prices from WisdomTree Issuer plc
- Man Group PLC Highlights Major Position in Ascential PLC
- Zhihu Inc. Undertakes Tender Offers for Class A Shares
- Nvidia Under Investigation: Exploring AI Market Compliance Issues
- Gareth Miller Joins Clean Energy Capital's Board at TGC
- Panasonic Readies for EV Battery Production in Japan
- Class Action Update: Super Micro Computer, Inc. Lawsuit Info
- Contango ORE Announces Significant Gold Production Update
- Know Your Rights as a Shareholder of NANO Nuclear Energy Inc.
- PDD Holdings Inc. Faces Legal Challenges Over Investor Rights
- Deadline Approaches for Shareholders in Lululemon Case
- Understand Your Rights as a Spire Global, Inc. Shareholder
- Extreme Networks Shareholder Action: Know Your Rights and Options
- Investors Urged to Act: Class Action Against Ardelyx, Inc. (ARDX) Made
- Starbucks Faces Securities Lawsuit Amid Shareholder Concerns
- Join the Class Action Against DXC Technology Today
- Indivior PLC Faces Class Action Lawsuit Over Misleading Statements
- Join the Symbotic Inc. Class Action: Important Deadline Ahead
- DexCom, Inc. Faces Legal Action for Shareholder Rights Protection
- Investors Alert: Take Action with Stellantis N.V. Class Action
- STMicroelectronics Faces Legal Action Over Stock Concerns - STM
- ODDITY Tech Ltd Faces Legal Action for Securities Violations
- Understand Your Rights: Join CrowdStrike Class Action Today
- Important Update for Ford Motor Company Investors on Class Action
- Taiwan's Export Milestone Driven by AI Chip Demand
- Navigating Stock Market Uncertainty Ahead of US Elections
- Pencils Protocol Achieves $80M Valuation Amid DeFi Innovations
- HIPPS Market Growth Expected to Reach $950 Million by 2032
- Innovative Trends Driving the Edible Packaging Market Forward
- International Petroleum Corporation Shares Repurchase Update
- IPC Enhances Shareholder Value with Recent Buyback Results
- Alchip Technologies Achieves Unprecedented Q2 Financial Success
- Alchip Technologies Unveils Comprehensive ESG Annual Report